Drug intelligence / Profile preview

ONO-7914

Development stage: Discontinued
Lead developer: Ono Pharmaceutical
Modality: Small Molecules
Administration: Oral (based On Typical Administration Route For Small Molecules; Specific Trial Protocols May Clarify Further)

Overview

ONO-7914 is a small molecule drug developed as an agonist of the STING (Stimulator of Interferon Genes) pathway. It is being investigated for its immunomodulatory and antitumor properties, specifically in the treatment of advanced or metastatic solid tumors. The drug works by activating the STING pathway, which plays a key role in innate immunity and can promote antitumor immune responses. Clinical trials are ongoing to evaluate its safety and tolerability both as monotherapy and in combination with other agents such as ONO-4538 (nivolumab), a PD-1 inhibitor[2][3][9].

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on ONO-7914.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONO-7914.

Explore the full profile